Crescita Therapeutics Inc CTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CAD 0.44
- Day Range
- CAD 0.44–0.44
- 52-Week Range
- CAD 0.36–0.73
- Bid/Ask
- CAD 0.44 / CAD 0.45
- Market Cap
- CAD 8.50 Mil
- Volume/Avg
- 23,000 / 17,376
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 4.62%
Company Profile
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 80
Valuation
|
Metric
|
CTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.46 |
Price/Sales | 0.50 |
Price/Cash Flow | 18.75 |
Price/Earnings
CTX
Financial Strength
|
Metric
|
CTX
|
|---|---|
Quick Ratio | 2.50 |
Current Ratio | 3.80 |
Interest Coverage | −22.96 |
Quick Ratio
CTX
Profitability
|
Metric
|
CTX
|
|---|---|
Return on Assets (Normalized) | −5.91% |
Return on Equity (Normalized) | −7.81% |
Return on Invested Capital (Normalized) | −8.74% |
Return on Assets
CTX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Hnkvbwckc | Zyrx | $76.6 Bil | |
MKKGY
| Merck KGaA ADR | Pyfcmxqqp | Xjnhcm | $72.3 Bil | |
HLN
| Haleon PLC ADR | Bmmcydm | Xrr | $37.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Nkkgsbr | Xktqk | $18.3 Bil | |
VTRS
| Viatris Inc | Kwxjhtvh | Vqxyb | $13.5 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mcjzhwvt | Cqj | $11.7 Bil | |
CTLT
| Catalent Inc | Wzschqylk | Jtnrnw | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Tcjhkbfps | Fzxy | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Ctfhqgpw | Lknb | $4.2 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Chqhwvqky | Fyfvrv | $3.5 Bil |